WPI 2235 Pill — BLACK;YELLOW CAPSULE, 22mm — Metronidazole

No photo available

Imprint	WPI / 2235
Colour	BLACK;YELLOW
Shape	CAPSULE
Size	22
Strength	TETRACYCLINE HYDROCHLORIDE 500 mg
Dosage form	Capsule
Manufacturer	Ailex Pharmaceuticals, LLC
NDC	70556-103
Schedule	—
Availability	—
Ingredients	TETRACYCLINE HYDROCHLORIDE[TETRACYCLINE]

What does this imprint mean?

The imprint "WPI 2235" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Metronidazole

Uses and warnings

BOXED WARNING: "Metronidazole has been shown to be carcinogenic in mice and rats" in long-term studies, and unnecessary use of the drug should be avoided. Contraindicated with known hypersensitivity to metronidazole or other nitroimidazole derivatives, in the first trimester of pregnancy for trichomoniasis, and with concurrent or recent (within 2 weeks) disulfiram use or alcohol/propylene-glycol-containing products due to disulfiram-like reactions. Also contraindicated in patients with Cockayne syndrome due to reports of severe hepatotoxicity/acute liver failure. Other warnings cover CNS effects (seizures, peripheral and optic neuropathy, encephalopathy) and severe cutaneous adverse reactions (SJS, TEN, DRESS).

Metronidazole tablets treat "trichomoniasis" (symptomatic and asymptomatic, including in male partners), "amebiasis" (intestinal disease and liver abscess), and serious infections caused by susceptible anaerobic bacteria involving the intra-abdominal cavity, skin and skin structure, gynecologic tract, central nervous system, lower respiratory tract, bone and joint, and endocarditis. The label stresses it should be used "only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria."

Read the full drug profile →